Page last updated: 2024-12-08

1-oxo-2-benzothiopyran-3-carboxylic acid methyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-Oxo-2-benzothiopyran-3-carboxylic acid methyl ester, also known as **methyl 2-oxo-2H-1-benzothiopyran-3-carboxylate** or **methyl 3-benzoylthiophene-2-carboxylate**, is a heterocyclic organic compound. Here's a breakdown of its structure and potential significance in research:

**Structure:**

* **Benzothiopyran core:** The molecule features a fused ring system containing a benzene ring and a thiopyran ring (a six-membered ring with one sulfur atom).
* **Keto group:** A carbonyl group (C=O) is present at position 1 of the thiopyran ring.
* **Carboxylic acid methyl ester:** A methyl ester (COOCH3) is attached at position 3 of the thiopyran ring.

**Importance in Research:**

This compound is a potential starting material or intermediate in organic synthesis and medicinal chemistry. Here's why:

* **Versatile building block:** The presence of the keto group and the ester functionality allows for various chemical modifications and transformations, making it a valuable building block for the synthesis of other complex molecules.
* **Potential biological activity:** Heterocyclic compounds like benzothiopyrans have shown various biological activities, including antibacterial, antifungal, and anti-inflammatory properties. This specific compound could be a lead compound for the development of new drugs or therapeutic agents.
* **Exploration of structure-activity relationships:** Researchers may synthesize derivatives of this compound by modifying the substituents on the benzene ring or the thiopyran ring. By studying the effects of these modifications on biological activity, researchers can gain insights into structure-activity relationships and optimize the compound for desired applications.

**Specific Research Applications:**

While specific research applications may vary, this compound could be relevant in the following areas:

* **Antimicrobial drug discovery:** Exploring its potential as an antibacterial or antifungal agent.
* **Anti-inflammatory drug discovery:** Investigating its potential to inhibit inflammation.
* **Synthesis of new materials:** As a building block for novel polymers, catalysts, or other functional materials.

**Further Research:**

To fully understand the importance of 1-oxo-2-benzothiopyran-3-carboxylic acid methyl ester, more research is needed to:

* **Determine its biological activities.**
* **Synthesize and evaluate its derivatives.**
* **Investigate its potential applications in different fields.**

**Note:** Information on the exact research applications of this specific compound might be limited due to its relative obscurity. However, its structural features and potential for modification make it a promising candidate for future investigation in diverse areas of research.

Cross-References

ID SourceID
PubMed CID345568
CHEMBL ID1604364
CHEBI ID107906

Synonyms (22)

Synonym
AKOS002183724
methyl 1-oxo-1h-isothiochromene-3-carboxylate
methyl 1-oxoisothiochromene-3-carboxylate
IFLAB1_005886
MLS000085563
smr000020498
nsc403269
nsc-403269
AP-906/42288221
IDI1_011289
CHEBI:107906
HMS1428L12
AB00413244-03
HMS2163L14
CCG-25169
F1470-0040
500779-37-3
HMS3314C21
CHEMBL1604364
1-oxo-2-benzothiopyran-3-carboxylic acid methyl ester
Q27186250
STL515125
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organic heterobicyclic compound
organosulfur heterocyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
P53Homo sapiens (human)Potency12.58930.07319.685831.6228AID504706
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency17.78280.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
flap endonuclease 1Homo sapiens (human)Potency79.43280.133725.412989.1251AID588795
VprHuman immunodeficiency virus 1Potency39.81071.584919.626463.0957AID651644
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency3.54810.00419.962528.1838AID2675
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency5.01191.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]